Industry News

- Read more about Dr.Reddy's launched Nise D spray in Indian Market
Strengthening its over the counter (OTC) portfolio, Pharma major Dr. Reddy's Laboratories on Monday announced the launch of Nise D spray, which offers quick and targeted pain killing.
- Read more about Sun Pharma completes tender offer for InSite Vision
Sun Pharmaceutical Industries Ltd.successfully completed cash tender offered by by Thea Acquisition Corp. (“Thea”), an indirect wholly owned subsidiary of Sun Pharma, for all outstanding shares of common stock of InSite Vision Incorporated (OTCBB: INSV, InSite), which expired at 12:00 midnight, New York City time, (the end of the day) on Tuesday, October 27, 2015.
- Read more about Novo Nordisk increased operating profit by 51%
16% local currency operating profit growth adjusted for the NNIT divestment

Sales increased by 23% in Danish kroner and by 9% in local currencies to DKK 79.1 billion.
- Sales of Victoza® increased by 39% (21% in local currencies)
- Sales of Levemir® increased by 27% (10% in local currencies).
- Sales in North America increased by 33% (10% in local currencies).
- Sales in International Operations increased by 23% (17% in local currencies).
- Sales in Region China increased by 26% (5% in local currencies).
- Read more about Awareness and Timely Management Key to bring Down Acute Liver Failure (ALF) Mortality: Experts
- 50% of ALF cases happen due to Hepatitis A&E, unavailability of clean potable water

- ALF mortality has come down to 20 % from 80 % in last 10 years due to advancement in liver intensive care and liver transplantation of ALF patients.

(NewsVoir); The expert team of Department of Hepatology at Global Hospitals - one of the fastest growing chains of multi-super speciality, multi-organ transplant and quaternary care hospitals in Mumbai, shared their experience in treating and managing Acute Liver Failure patients medically and through transplantation.

[adsense:336x280:8701650588]
- Read more about Dabur India posts 18.7 percent increase in net profit in Q2
Dabur India on announced 18.7 percent increase in its net consolidated profit at Rs.341.1 crore for the quarter ended September 30 as against Rs.287.5 crore in the year-ago period.
- Read more about Future Generali India plans to expand health portfolio
Non-life insurer Future Generali India Insurance Company Ltd. hopes to increase its retail health insurance business with its new product, a senior official said on Wednesday.
- Read more about NATCO launches HEPCINAT LP in Nepal
Natco Pharma has launched the first licensed generic version of ledipasvir+sofosbuvir combination in Nepal, under its brand name Hepcinat LP.

[adsense:336x280:8701650588]
- Read more about Max Healthcare Partners Smart Health City to Operate and Manage South Delhi based Saket City Hospital
Max Healthcare (MHC) today announced a partnership with Smart Group wherein MHC would acquire 51% stake in Saket City Hospital Pvt. Ltd., from Smart Health City Pte Ltd, the Singapore based BK Modi Group company which manages and operates the Delhi based Saket City Hospital (SCH). The transaction is subject to confirmatory diligence, requisite regulatory approvals and other customary conditions.
- Read more about US FDA accepts Turing Pharma's IND application and Fast Track Designation for TUR-004 to treat epileptic encephalopathies
The US Food and Drug Administration (FDA) has cleared Turing Pharmaceuticals AG's Investigational New Drug (IND) application for TUR-004 in the treatment of epileptic encephalopathies. In addition, TUR-004 has been granted Fast Track designation.
- Read more about Resverlogix start phase 3 trial with apabetalone
Resverlogix Corp. announced the commencement of a phase 3 clinical trial called 'BETonMACE' with lead drug apabetalone (RVX-208) in high-risk patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM). Resverlogix has received initial approval from the regulatory authority and ethics committee in the first three countries: Belgium, Hungary and Israel, which will represent approximately 15 investigative sites of an expected 175 site trial. The first site initiation visit was held yesterday and with drug now available to the centers, enrollment of patients will commence. Over the course of the coming months, additional investigative sites will be activated.